In April 2014, a tamper-resistant controlled-release
oxycodone formulation was released in Australia. We aimed to determine whether
there are latent classes of people who tamper with pharmaceutical opioids based
on frequency of opioid and illicit drug use, the demographic and clinical
profiles of these groups, and if there were changes in use and harms following
the introduction.
A prospective cohort of 606 people who regularly tamper with
pharmaceutical opioids was interviewed January to March 2014 (Wave 1) and May
to August 2014 (Wave 2). Latent class analysis identified groups based on
non-prescribed opioid, illicit drug and prescribed opioid substitution therapy
(OST) use at Wave 1. Regression models examined whether group membership
predicted use and harms at Wave 2.
Four groups were identified:
- frequent OST group (39%),
- mixed OST/heroin group (7%),
- infrequent pharmaceutical opioid and heroin group (44%)
- and frequent oxycodone group (25%).
Despite heterogeneity among people who tamper with
pharmaceutical opioids, the tamper-resistant formulation was followed by
reductions in oxycodone tampering among high-frequency and low-frequency users.
There was no evidence of increased use of other opioids or illicit drugs.
Via: http://ht.ly/SXxZf Purchase
full article at: http://goo.gl/HF0ZPd
By: Peacock A1, Degenhardt L2, Larance B2, Cama E2, Lintzeris N3,4, Ali R5, Bruno R1.
- 1School of Medicine (Psychology), University of Tasmania, Hobart, Tasmania, Australia.
- 2National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia.
- 3Discipline of Addiction Medicine, Faculty of Medicine, Sydney University, Sydney, New South Wales, Australia.
- 4The Langton Centre, South East Sydney Local Health District (SESLHD) Drug and Alcohol Services, Sydney, New South Wales, Australia.
- 5University of Adelaide, Adelaide, South Australia, Australia.
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment